Online citations, reference lists, and bibliographies.
← Back to Search

Epirubicin And Cyclophosphamide Versus Epirubicin And Docetaxel As First-line Therapy For Women With Metastatic Breast Cancer: Final Results Of A Randomised Phase III Trial.

J. Blohmer, P. Schmid, J. Hilfrich, K. Friese, A. Kleine-Tebbe, H. Koelbl, H. Sommer, G. Morack, M. Wischnewsky, W. Lichtenegger, S. Kuemmel
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND This randomised phase III trial was carried out to compare the efficacy and safety of epirubicin and cyclophosphamide (EC) with epirubicin and docetaxel (Taxotere) (ED) as first-line chemotherapy for metastatic breast cancer. PATIENTS AND METHODS Patients (n = 240) were randomly assigned to receive either ED (epirubicin 75 mg/m(2) and docetaxel 75 mg/m(2)) or EC (epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2)). The primary end point was objective response rate (ORR). Secondary end points were progression-free survival (PFS), overall survival (OS), and safety. RESULTS ORR for patients randomly assigned to receive EC and ED were 42% and 47%, respectively (P = 0.63). Median PFS [10.1 versus 10.3 months; hazard ratio (HR) 0.98; log-rank P = 0.38] and OS (19.9 versus 30.0 months; HR 0.663; log-rank P = 0.21) were comparable in both arms. Although grade 3/4 leucopenia occurred more frequently with ED (81% versus 73%; P = 0.01), there were no significant differences in the incidence of febrile neutropenia and grade 3/4 infections. Grade 3/4 non-haematologic toxicity was infrequent in both arms. Congestive heart failure was observed in one patient in each arm. CONCLUSION In this randomised trial, no differences in the efficacy study end points were observed between the two treatment arms.
This paper references
10.1200/JCO.2003.04.040
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
J. Nabholtz (2003)
10.1007/s10549-005-9150-3
Fruits, vegetables, and micronutrient intake in relation to breast cancer survival
B. Fink (2005)
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates: an international randomized phase III study in metastatic breast cancer
G Brufman (1997)
10.1200/JCO.2003.08.013
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
G. Sledge (2003)
10.1200/JCO.2002.09.002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
J. O'Shaughnessy (2002)
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: the 303 study group
S Chan (1999)
Goeretzlehner
10.1023/A:1008295427877
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group.
G. Brufman (1997)
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
J. Nabholtz (1999)
10.1200/JCO.2007.10.8399
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
M. Piccart-Gebhart (2008)
Graffunder
10.1200/JCO.1993.11.7.1253
Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial.
C. Focan (1993)
Koennecke
10.1200/JCO.2005.06.236
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
M. Bontenbal (2005)
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients
French Epirubicin (1991)
Wolf
Safety and efficacy of first-line epirubicin–docetaxel versus epirubicin–cyclophosphamide: updated results of multicentre randomised phase III trial in metastatic breast cancer
J-U Blohmer (2005)
10.1200/JCO.2001.19.6.1707
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
J. Jassem (2001)
Doubling epirubicin dose intensity (100 mg/m 2 versus 50 mg/m 2 ) in the FEC regimen significantly increases response rates: an international randomized phase III study in metastatic breast cancer
G Brufman
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients
French Epirubicin Study Group (1991)
Albrecht
10.1200/JCO.2002.11.005
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
L. Biganzoli (2002)
10.1200/JCO.2000.18.4.724
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
R. Paridaens (2000)
Ann Oncol
(1997)
10.1200/jco.2000.18.17.3115
Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.
(2000)
10.1200/JCO.1999.17.5.1413
Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy
J. M. Nabholtz (1999)
10.1200/JCO.2007.10.8407
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
T. Burzykowski (2008)
Jub
Dose-response relationship of epirubicinbased first-line chemotherapy for advanced breast cancer: a prospective randomized trial
C Focan (1993)
Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC) Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group
Hj Luck (2000)
10.1200/JCO.2004.22.14_SUPPL.627
Safety and efficacy of first-line epirubicin-docetaxel (ED) versus epirubicin-cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC).
J. Blohmer (2004)
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer
Gw Sledge (2003)
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: EORTC 10961
L Biganzoli (2002)
Schreiber
10.1038/sj.bjc.6602179
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
J. Bonneterre (2004)
10.1200/JCO.1996.14.4.1146
Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
L. Bastholt (1996)
Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.
N. Marschner (1994)
10.1200/JCO.1999.17.8.2341
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
S. Chan (1999)



This paper is referenced by
10.1007/s00280-014-2602-x
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
D. Mahalingam (2014)
10.1093/annonc/mdv619
Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.
J. Truong (2016)
10.1007/S13556-013-0004-8
Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer
C. Angelis (2013)
10.1007/s12609-012-0098-0
Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development
Marie-Catherine Vanderbeeken (2013)
10.1016/j.clbc.2017.07.015
Progression‐Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta‐Analysis of 37 Trials
L. Li (2018)
10.1097/MD.0000000000000803
Role of Taxane and Anthracycline Combination Regimens in the Management of Advanced Breast Cancer
R. Zheng (2015)
10.1016/j.ejca.2011.06.018
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
X. Pivot (2011)
10.1200/JCO.2014.56.7479
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
A. Partridge (2014)
10.1016/j.ejca.2011.08.004
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
E. Curtit (2011)
10.1016/j.clbc.2015.09.007
Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
J. Sachdev (2016)
10.1007/s00280-019-03948-6
Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study
T. Sakurada (2019)
10.26481/DIS.20171213BV
Neoadjuvant chemotherapy in breast cancer : efficacy, response assessment and axillary strategy
B. E. Vriens (2017)
10.1016/j.ctrv.2012.04.005
If there is no overall survival benefit in metastatic breast cancer: does it imply lack of efficacy? Taxanes as an example.
B. E. Vriens (2013)
First-Line Chemotherapy with Anthracycline and Taxane Combination in Metastatic Breast Cancer. Detection of bone metastases with TRACP 5b
J. Korpela (2011)
Materials and Methods: a Systematic Literature Search Was Conducted for Full-length Articles Reporting Fn Rates for Reviews Annals of Oncology
D C Stein ()
10.1002/14651858.CD003366.pub3
Taxane-containing regimens for metastatic breast cancer.
D. Ghersi (2015)
Semantic Scholar Logo Some data provided by SemanticScholar